How a Chicago health system is tackling racial disparities

To tackle health disparities between Chicago’s West Side and wealthier, predominantly white neighborhoods elsewhere in the city, Rush University Medical Center is leading a group of nine hospitals and health systems to make investments and hire people from disadvantaged communities.

Part of Rush’s $1 million investment helped launch Chicago Neighborhood Rebuild, a job training program in the city’s three most violent police districts. The results haven’t been perfect—one of the workers interviewed by Chicago magazine, 24-year-old Corina Ransburg, was dismissed from her job cleaning city streets after only a few months because of a dispute when she accepted, and then declined, an offer to join a 13-month Rush-run robotics and electrical manufacturing training program.

Those kinds of inflexibilities can hurt programs started by nonprofit hospitals, according to Darnell Shields, a member of the planning committee of the West Side Total Health Collaborative.

“You might say this population struggles with that or this need, but then as you start to drill down and start to work specifically with individuals, the obstacles and the barriers can range and have a lot of variance,” Shields said. “It can be child care, it can be all of these different things. So if (your program’s) too rigid, you can really set things up for failure.”

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.